This article has a correction
Please see: What should be done about mephedrone?
- Adam R Winstock, senior lecturer in addiction psychiatry 1,
- John Marsden, reader in addiction psychology1,
- Luke Mitcheson, consultant clinical psychologist2
- 1Institute of Psychiatry, King’s College London, London SE5 8AF
- 2South London and Maudsley NHS Trust, London SE5 8AZ
- adam.winstock{at}kcl.ac.uk
The recent deaths of two young men who are thought to have taken the β keto-amphetamine stimulant mephedrone (4-methylmethcathinone) have prompted urgent calls for the drug to be banned. As we write, there is no certainty that mephedrone caused these two deaths, but it may be implicated. Amphetamine-type stimulants are known to cause about 100, mostly accidental, deaths a year in the United Kingdom.1 Stimulant related deaths typically result from a sympathomimetic toxidrome—a constellation of symptoms and signs that can be seen with excessive consumption of stimulant type drugs—accompanied by cardiac conduction problems, cerebral haemorrhage, and sometimes hyperpyrexia. Other drugs and alcohol are commonly used at the same time,1 and may have been in the latest cases. Most drug related deaths (about 1100 cases a year in the UK) involve one or more central nervous system depressants—including opioids, alcohol, and sedatives—at doses that cause respiratory depression.2
Almost unheard of two years ago, mephedrone—colloquially known as “Miaow,” “4-MMC,” “Meph,” and “TopCat”—has grown quickly in popularity and is now widely available for purchase online. So called “legal highs” have been available for decades, but recently web based marketing has facilitated their profitable sale. It is hard to determine the risks …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record







CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Ventilator associated pneumonia
Published 30 May 2012
Re: Restless legs syndrome
Published 30 May 2012
Author's reply
Published 30 May 2012
Re: Full access to trial data holds many benefits and a few pitfalls, conference hears
Published 30 May 2012
Restless Legs Syndrome: Fact or Fiction
Published 30 May 2012
Most responses
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (12 responses)
Published 10 May 2012 - 23:32
The psychiatric oligarchs who medicalise normality (9 responses)
Published 2 May 2012 - 15:42
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27